EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib By Ogkologos - May 22, 2026 273 0 Facebook Twitter Google+ Pinterest WhatsApp Palbociclib Viatris is a generic of Ibrance which has been authorised in the EU since 2016 Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Receiving a Blood Transfusion During Cancer: What to Know and What... October 19, 2023 Weekend in New England June 30, 2020 How Some Brain Tumors Hijack the Mind to Grow June 21, 2023 Judge Rules That 3-Year-Old Child With Leukemia Must Get Chemo Against... May 16, 2019 Load more HOT NEWS The Right to be Forgotten: ESMO Calls on EU Countries to... EMA Publishes Guidance to Provide Key Methods and Good Regulatory Practices... ESMO awards its first fellowship to support digital and computational pathology How Sharing My Story Helps Me Cope With an Advanced Brain...
